Organogenesis Corp (ORGO) Long-Term Debt to Capital Coefficient

This daily price chart for Organogenesis Holdings (ORGO) reflects the performance of a company with a metric of 0.20. The business leverages growing surgeon interest in innovative therapies for diabetic ulcers. Biomaterial production is concentrated within in-house facilities to ensure quality control, while external partners handle only the IT sector. Complex patents and lengthy regulatory approval processes for government protocols create a high barrier to entry.

For Organogenesis Holdings, which is expanding its presence in the regenerative medicine segment, an analysis of long-term liabilities relative to equity determines the extent to which development depends on borrowed funds. The trend in the long-term debt-to-equity ratio demonstrates a balance between securing external financing for chronic wound therapies and financial autonomy, confirming the business model's resilience to debt risks while scaling the customer base.